Journal of agricultural and food chemistry
Cure8 research brief
Why This Matters
The work suggests a fungus-derived metabolite can reduce experimental colitis through AhR and NF-κB pathways, highlighting a potential new direction for microbiome‑based therapies or postbiotics that could eventually affect IBD treatment strategies.
Who Should Pay Attention
Researchers studying the gut microbiome/mycobiome, immune pathways (AhR, NF-κB), and experimental therapeutics; clinicians interested in emerging preclinical IBD research; patients curious about microbiome-related science (as early-stage, preclinical findings).
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
The paper describes experiments in a DSS-induced colitis model in mice where gavage with A. ruber lessened weight loss, disease activity index, colon shortening, and tissue injury. Metabolomics of fungal cultures identified 3‑methyldioxyindole; treatment with the purified compound reproduced beneficial effects.
Mechanistic data in the abstract indicate the effect was AhR‑dependent and blocked by an AhR antagonist, with associated reductions in markers of NF-κB activation. This is reported at the abstract level in a Journal of Agricultural and Food Chemistry article; the extract provided is partial and focused on preclinical mouse and in vitro work.
The results are promising for basic research into microbiome‑derived metabolites but are not clinical evidence that this approach is safe or effective in people. Researchers should view this as a preclinical, mechanism‑focused study that supports further investigation of fungal metabolites and AhR signaling in colitis.
Keep In Mind
this is preclinical research reported in an abstract and uses a mouse DSS model plus in vitro assays. Findings in animal models do not necessarily translate to humans; safety, dosing, and efficacy in people would require substantial further study.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationJournal of agricultural and food chemistry
AuthorsHaoming Li, Shuiling He, Qinqin Qiao +2 more
InstitutionThird Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Taiyuan 030032, China.
Study typeJournal article
Indexed viaPubMed
Source typeResearch paper
PublishedJul 9, 2026, 12:00 AM
Content availableJournal abstract
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Cimicifuga foetida L. polysaccharide alleviates ulcerative colitis by inhibiting pyroptosis and regulating gut microbiota
Researchers are exploring plant-derived polysaccharides as potential therapies that might reduce inflammation and protect the intestinal barrier. For people with UC, therapies that reduce pyroptosis and restore...
Osbeckia opipara attenuates inflammation and reconstructs the intestinal barrier in ulcerative colitis by modulating the AHR/IL-22/STAT3 signaling axis.
The study suggests a plant-derived AHR-activating mechanism that reduced inflammation and repaired the intestinal barrier in preclinical ulcerative colitis models, a pathway that could be relevant to future therapies or...
Colon-targeting pH-responsive Bletilla striata polysaccharide coacervate microdroplets for ulcerative colitis therapy via macrophage reprogramming
The study describes a new oral, colon‑targeted delivery system that improved outcomes in a mouse model of ulcerative colitis and shifted immune and microbiome markers—research that could inform future therapies focused...